Hajime Asahina
5PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Nov 05, 2025
Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study.Takehiro Tozuka, Yoko Tsukita, Kohei Kushiro
|May 04, 2023
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial.Kazutaka Fujita, Ryo Arai, Satoshi Shoji
|Mar 31, 2023
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.Daisuke Morinaga, Hajime Asahina, Shotaro Ito
|Jul 21, 2018
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).Taichi Takashina, Hajime Asahina, Satoshi Oizumi
|Sep 15, 2017
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).Yasuyuki Ikezawa, Hajime Asahina, Satoshi Oizumi
Pageof 1
